- Home
- CFR vs LEGN Comparison
CFR vs LEGN Comparison
Compare CFR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CFR
- LEGN
- Stock Information
- Founded
- CFR 1868
- LEGN 2014
- Country
- CFR United States
- LEGN United States
- Employees
- CFR N/A
- LEGN N/A
- Industry
- CFR Major Banks
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- CFR Finance
- LEGN Health Care
- Exchange
- CFR Nasdaq
- LEGN Nasdaq
- Market Cap
- CFR 8.1B
- LEGN 6.3B
- IPO Year
- CFR N/A
- LEGN 2020
- Fundamental
- Price
- CFR $124.08
- LEGN $32.01
- Analyst Decision
- CFR Hold
- LEGN Strong Buy
- Analyst Count
- CFR 16
- LEGN 12
- Target Price
- CFR $138.44
- LEGN $70.82
- AVG Volume (30 Days)
- CFR 484.0K
- LEGN 1.3M
- Earning Date
- CFR 10-30-2025
- LEGN 11-12-2025
- Dividend Yield
- CFR 3.22%
- LEGN N/A
- EPS Growth
- CFR 20.47
- LEGN N/A
- EPS
- CFR 9.72
- LEGN N/A
- Revenue
- CFR $2,141,575,000.00
- LEGN $796,838,000.00
- Revenue This Year
- CFR $13.87
- LEGN $68.68
- Revenue Next Year
- CFR $4.09
- LEGN $48.49
- P/E Ratio
- CFR $12.77
- LEGN N/A
- Revenue Growth
- CFR 9.02
- LEGN 74.75
- 52 Week Low
- CFR $100.31
- LEGN $27.34
- 52 Week High
- CFR $147.64
- LEGN $47.79
- Technical
- Relative Strength Index (RSI)
- CFR 48.60
- LEGN 44.21
- Support Level
- CFR $119.37
- LEGN $31.58
- Resistance Level
- CFR $124.87
- LEGN $32.80
- Average True Range (ATR)
- CFR 2.81
- LEGN 0.98
- MACD
- CFR 0.02
- LEGN 0.07
- Stochastic Oscillator
- CFR 67.72
- LEGN 29.24
About CFR Cullen/Frost Bankers Inc.
Cullen/Frost is a regional US bank with around $50 billion in assets (as of mid-2025), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based approach to banking that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through branch openings. The bank's sweet spot is small to medium-size Texas-based commercial clients.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.